MPM BioImpact's Aktis Eyes $212 Million from IPO

Aktis Oncology Inc., which operates in the clinical-stage of biotechnology innovation, is making strides to secure up to $212 million through an IPO in the United States. The focus of the company is on the development and application of radiopharmaceuticals for therapeutic purposes.

IPO Details and Valuation

Supported by MPM BioImpact alongside Vida Ventures, the company plans to issue 11.8 million shares priced between $16 to $18 each. Should the shares hit the upper pricing, the firm based in Boston is projected to achieve a market capitalization of approximately $840 million, as inferred from the shares specified in their submission to the US Securities and Exchange Commission.